- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06154382
Eltroxin Administration to Patients With Extremely Low T4 Values in the Intensive Care Unit
Eltroxin Administration to Patients With Extremely Low T4 Values in the Intensive Care Unit: Comparison Between Groups and Therapeutic Outcomes
Nonthyroidal illness (formerly called sick euthyroid syndrome) is a common condition in patients hospitalized in the intensive care unit, and it is caused by changes in the levels of thyroid hormones in the blood . These changes are correlated to the severity of the critical illness, morbidity and mortality. This condition is characterized by low serum T3 levels, high rT3 levels, normal or low T4 levels, and normal or low TSH levels. Previous studies have shown a relationship between NTIS (nonthyroidal illness) and poor therapeutic outcomes in patients admitted with sepsis, multi trauma, ARDS, acute respiratory failure, septic shock and mechanically ventilated patients in intensive care .
In general, the recommendation is not to routinely take blood tests to evaluate thyroid function in critical patients in the intensive care unit, unless they were previously known to have a thyroid disease or there is a clinical suspicion that such a disorder developed during hospitalization in the intensive care unit. Also, studies so far have not shown an advantage for eltroxin administration to intensive care patients with low T3 and/or T4 levels when the laboratory tests indicate NTIS. However, there is a specific group of patients, with NTIS and extremely low T4 levels (less than 50% of the lower limit of the normal range) who have a particularly high mortality rate in intensive care (over 85%) and in whom it has not been investigated whether the administration of eltroxin will improve the therapeutic outcomes ( , i.e. was such a low T4 level in them considered a marker for the severity of their general critical illness, or is it another disorder in itself, the treatment of which would benefit the patient) . We would like to examine whether the administration of eltroxin in this specific group of patients, which has not been studied so far, will be beneficial in improving the therapeutic outcomes
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
-
Kfar Saba, Israel
- Meir Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
All patients aged 18--99 who were admitted to the general intensive care unit from January 2016 to November 22, 2023 for any reason, and who during their hospitalization in the intensive care unit had lower than normal T4 levels measured. It is about 350 patients. Of these, we will specifically examine the group of patients for whom an extremely low level of T4 was measured (less than 50% of the lower limit of the norm).
-
Description
Inclusion Criteria: All patients aged 18--99 who were admitted to the general intensive care unit from January 2016 to November 22, 2023 for any reason, and who during their hospitalization in the intensive care unit had lower than normal T4 levels measured. It is about 350 patients. Of these, we will specifically examine the group of patients for whom an extremely low level of T4 was measured (less than 50% of the lower limit of the norm).
-
Exclusion Criteria: Patients who were known to have a chronic thyroid dysfunction prior to their hospitalization in the unit, patients who were regularly treated with eltroxin prior to their hospitalization
-
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
group 1: eltroxin administration
patients witn low T4 level who recieved eltroxin in ICU
|
eltroxin administration
|
group 2: no eltroxin administration
patients witn low T4 level who did not recieve eltroxin in ICU
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
28-day mortality
Time Frame: 28-day mortality
|
To examine whether there are differences in mortality within 28 days in intensive care patients with NTIS and extremely low levels (less than 50% of the lower limit of normal) of T4 between a group of patients who received eltroxin and another who did not.
|
28-day mortality
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 0290-23-MMC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thyroid; Functional Disturbance
-
Yale UniversityWithdrawn
-
University of California, IrvineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingHypothyroidism | Hemodialysis | Thyroid; Functional DisturbanceUnited States
-
University of DebrecenCompletedThyroid; Functional Disturbance | Dietary Iodine Deficiency
-
Princess Anna Mazowiecka Hospital, Warsaw, PolandRecruiting
-
Loma Linda UniversityTerminatedHeart; Functional DisturbanceUnited States
-
Guangdong Provincial People's HospitalUnknownKidney; Functional DisturbanceChina
-
AstraZenecaCompletedHepatic; Functional DisturbanceUnited States
-
Far Eastern Memorial HospitalCompletedHeart; Functional DisturbanceTaiwan
-
Centre Hospitalier Universitaire de BesanconNot yet recruitingAging | Functional Disturbance | Home
-
University of CopenhagenRigshospitalet, Denmark; Glostrup University Hospital, Copenhagen; Agroscope... and other collaboratorsTerminatedHealthy | Ileostomy; Functional DisturbanceDenmark
Clinical Trials on Eltroxin administration
-
Sheba Medical CenterUnknownCentral Hypothyroidism
-
Sheng-Chiang SuWithdrawn
-
Herlev HospitalCenter for Diabetes Research, Herlev and Gentofte Hospital.Completed
-
Herlev HospitalCompleted
-
University of AarhusMR Research Center, Skejby Sygehus, Brendstrupgaardsvej 100, 8200 Aarhus NTerminated
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do SulUnknownAging | Interaction Drug Food | Primary HypothyroidismBrazil
-
Camilo Jose Cela UniversityCompleted
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingAnalgesia | Acute Pain Due to TraumaNetherlands
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated